Immune thrombocytopenia, severe hematological consequence in a patient with COVID-19: A case report

xlomafota13 shared this article with you from Inoreader Immune thrombocytopenia, severe hematological consequence in a patient with COVID-19: A case report Via Experimental and therapeutic medicine Exp Ther Med. 2021 Sep;22(3):1043. doi: 10.3892/etm.2021.10475. Epub 2021 Jul 21. ABSTRACT Since the first appearance of coronavirus disease 2019 (COVID-19), multiple studies have focused on this novel coronavirus. Within a few months, the clinical and paraclinical manifestations and the mechanisms by which these changes are induced were elaborated. Clinically, the virus mainly causes the common cold, but can also result in severe or fatal pneumonia/acute respiratory syndrome. Regarding the biological changes, similar to any other virus, it can lead to a reduced lymphocyte count. The second most common change is represented by a reduced thrombocyte count. Furthermore, most patients have blood clotting abnormalities, inflammatory syndrome, raised D-dimer and lactate dehydrogenase levels. Detection of immune thrombocytopenia in asymptomatic patients who tested positive for COVID-19 justifies the need to perform differential diagnosis and testing for COVID-19. Typically, patients with severe forms of COVID-19 develop mild thrombocytopenia, while severe thrombocytopenia is rarely reported. The aim of this case report was to present the situation in which one asymptomatic patient who tested positive for COVID-19 developed severe immune thrombocytopenia. PMID:34373729 | PMC:PMC8343625 | DOI:10.3892/etm. 2021.10475 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.